Skip to main content

Table 5 Sensitivity analysis, with travel region as main parameter affecting the results.

From: Effectiveness and economic analysis of the whole cell/recombinant B subunit (WC/rbs) inactivated oral cholera vaccine in the prevention of traveller's diarrhoea

  Provider perspective Societal perspective Benefit-Cost  
  Net present value (€) Net present value (€) ratio Δ
Base case -30,958.12 79,280.45 1.39  
Region of travel     
Africa -31,036.87 75,474.24 1.32 ↓ 4.8%
C-S. America -31,219.34 48,944.96 0.86 ↓ 38.3%
India and SE. Asia -30,809.61 88,856.44 1.55 ↑ 12.1%